Abstract

COMPARATIVE IN-VITRO EVALUATION OF MARKETED TABLET FORMULATIONS (BRANDED VS. GENERIC) OF CLOPIDOGREL BISULPHATE 75 MG

Namdeo Shinde*, Ankita Parit, Ahilya Kale, Rutuja Salunke, Rutika Jadhav, Sakshi Salunke and Pravin Doke

ABSTRACT

A brand name medication and its generic version must contain the same API, dose, purity, quality, strength and active ingredient release. To ensure that the branded and generic formulations are pharmaceutically equivalent we evaluated the commonly used CVDs for their all the evaluation parameters as that of branded formulations. The two branded and two generic tablets of Clopidogrel Bisulfate, namely Clopivas, Deplatt, Clopicard and Clopidogrel IP 75 mg respectively have been analyzed according to the monographs of IP/BP/USP. Clopidogrel Bisulphate is an oral antiplatelet agent used to suppress blood clots, peripheral artery or cerebrovascular disorders in coronary arteries, and to prevent myocardial infarction. From experimental evaluation here we conclude that generic drugs shown similar results as that of branded drugs, hence the generic drug are much efficacious as that of branded drug.

Keywords: API, Purity, Quality, Strength, Clopidogrel Bisulfate, Clopivas, Deplatt, Clopicard, OTC medication.